A global, Phase 3 trial of approximately 20,000 older adult volunteers for the Bavarian Nordic A/S MVA-BN RSV vaccine candidate began this week and is expected to produce results by mid-2023.

The randomized, double-blind test will gather those aged 60 years and older in both the United States and Germany to assess the MVA-BN RSV vaccine’s efficacy against lower-respiratory tract disease caused by a respiratory syncytial virus (RSV). RSV is a common virus that can cause a range of symptoms, from mild, cold-like effects to more severe impacts such as bronchiolitis and pneumonia, which can lead to death, particularly among the very young or very old.

Read more...